Core Insights - Corbus Pharmaceuticals has reported significant clinical progress with its drug candidates, particularly CRB-701, which showed promising efficacy in treating head and neck squamous cell carcinoma (HNSCC) and cervical cancer [2][7][8] - The company has successfully completed a $75 million public offering, enhancing its financial position to support operations through 2028 [2][14] - Upcoming plans include a meeting with the FDA in Q1 2026 to discuss CRB-701 data and the initiation of a Phase 2/3 registrational study by mid-2026 [7][12] Corporate and Program Updates - CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, demonstrating an overall response rate (ORR) of 47.6% in HNSCC and 37.5% in cervical cancer at a dose of 3.6 mg/kg [3][8] - The company presented dose optimization data at ESMO 2025 and hosted a KOL event featuring insights from leading experts in HNSCC [4] - CRB-913, an oral small molecule CB1 receptor inverse agonist for obesity, is expected to complete its single ascending dose and multiple ascending dose studies by the end of 2025 [10][17] Financial Results - For the quarter ended September 30, 2025, the company reported a net loss of approximately $23.3 million, compared to a net loss of $13.8 million for the same period in 2024 [12] - Operating expenses increased to approximately $24.4 million, primarily due to higher clinical development costs [13] - As of September 30, 2025, the company had $104.0 million in cash and equivalents, bolstered by recent fundraising efforts [14]